Concepedia

Hideo Naganuma

HN

Statistics

Publications

26

Citations

2.2K

H-Index

19

Active since

1982

Affiliations

Daiichi-Sankyo (Japan)(Current)

Eli Lilly (United States)

Daiichi Sankyo (Germany)

Biomedical Research Laboratories (United States)

Eli Lilly (United Kingdom)

Hideo Naganuma is an author at Daiichi-Sankyo (Japan) specializing in pharmacology, medicine, and clinical pharmacology.

Publications per year

1982–2007

26

Publications

26

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

John T. Brandt, Christopher D. Payne, Stephen D. Wiviott et al. · American Heart Journal · 2006 · 570 citations

Medicine, Pharmacokinetics, Pharmacology +17

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters et al. · European Heart Journal · 2006 · 536 citations · Full text

Medicine, Cardiology, Pharmacology +17

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humans

Joseph A. Jakubowski, Nobuko Matsushima, Fumitoshi Asai et al. · British Journal of Clinical Pharmacology · 2006 · 128 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humans

Fumitoshi Asai, Joseph A. Jakubowski, Hideo Naganuma et al. · Platelets · 2006 · 108 citations

Medicine, Pharmacokinetics, Pharmacology +14

Brain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain

Takeshi Shiiki, Sumio Ohtsuki, Atsushi Kurihara et al. · Journal of Neuroscience · 2004 · 98 citations · Full text

Medicine, Neuroscience, Pharmacology +15

1–5 of 26